A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of capecitabine (Xeloda) in participants
who have undergone surgery for colon cancer. Oral Xeloda will be administered twice daily in
3-week cycles for a total of up to 8 cycles. The anticipated time on study treatment is 24
weeks, and the target sample size is 70 individuals.